Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (261-270 of 414) with videos related to

Pageof 42
Sort By:
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
The Journal of Allergy and Clinical Immunology|May 25, 2020
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotypeSamantha Slight-Webb, Miles Smith, Aleksandra Bylinska, et al.
Arthritis and Rheumatism|June 10, 2010
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trialJ T Merrill, R Burgos-Vargas, R Westhovens, et al.
The Journal of Rheumatology|February 3, 2012
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritisPeter M Izmirly, Marianna Shvartsbeyn, Shane Meehan, et al.
Arthritis Care & Research|March 9, 2026
Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus ActivityAlberto Nordmann-Gomes, Leila Khalili Msn, Cynthia Aranow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Arthritis Care & Research|October 10, 2017
Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World CliniciansAnca D Askanase, Samantha C Nguyen, Karen Costenbader, et al.
Lupus Science & Medicine|April 17, 2018
Lupus community panel proposals for optimising clinical trials: 2018Joan T Merrill, Susan Manzi, Cynthia Aranow, et al.
Viruses|September 28, 2024
Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance ProgramMichael L Farrell, Anton V Bryksin, Emily Ryan, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Pageof 42

Showing results (261-270 of 414) with videos related to

Sort By:
Pageof 42
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
The Journal of Allergy and Clinical Immunology|May 25, 2020
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotypeSamantha Slight-Webb, Miles Smith, Aleksandra Bylinska, et al.
Arthritis and Rheumatism|June 10, 2010
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trialJ T Merrill, R Burgos-Vargas, R Westhovens, et al.
The Journal of Rheumatology|February 3, 2012
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritisPeter M Izmirly, Marianna Shvartsbeyn, Shane Meehan, et al.
Arthritis Care & Research|March 9, 2026
Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus ActivityAlberto Nordmann-Gomes, Leila Khalili Msn, Cynthia Aranow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Arthritis Care & Research|October 10, 2017
Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World CliniciansAnca D Askanase, Samantha C Nguyen, Karen Costenbader, et al.
Lupus Science & Medicine|April 17, 2018
Lupus community panel proposals for optimising clinical trials: 2018Joan T Merrill, Susan Manzi, Cynthia Aranow, et al.
Viruses|September 28, 2024
Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance ProgramMichael L Farrell, Anton V Bryksin, Emily Ryan, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Pageof 42